In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England. Merck, Sharp, and Dohme (MSD)’s Keytruda (pembrolizumab ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C ...

Keytruda is a type of immunotherapy medication for treating certain types of cancer. Your doctor can check for signs that Keytruda is working with blood tests, imaging scans, and physical ...